TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments

TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.

Details

TapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors

TapImmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately $6.82 million in a private placement transaction with accredited investors and from the exercise of certain outstanding Series E warrants by certain existing institutional investors.

Details